These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 6268131

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Antihypertensive efficacy of once daily MK-521, a new nonsulfhydryl angiotensin-converting enzyme inhibitor.
    Rotmensch HH, Vlasses PH, Swanson BN, Irvin JD, Harris KE, Merrill DG, Ferguson RK.
    Am J Cardiol; 1984 Jan 01; 53(1):116-9. PubMed ID: 6318543
    [Abstract] [Full Text] [Related]

  • 23. Experience with perindopril in normal volunteers.
    Waeber B, Nussberger J, Perret L, Santoni JP, Brunner HR.
    Arch Mal Coeur Vaiss; 1989 May 01; 82 Spec No 1():35-41. PubMed ID: 2549899
    [Abstract] [Full Text] [Related]

  • 24. Acute hemodynamic and hormonal effects of MK-521 in congestive heart failure.
    Dickstein K, Aarsland T, Woie L, Kremer D, Abrahamsen AM.
    Scand J Urol Nephrol Suppl; 1984 May 01; 79():125-7. PubMed ID: 6089311
    [Abstract] [Full Text] [Related]

  • 25. A potent converting enzyme inhibitor CGS 13928C. Drug profile in normal volunteers.
    Schaller MD, Brunner DB, Nussberger J, Turini GA, Sen SB, Chen D, Waeber B, Brunner HR.
    Eur J Clin Pharmacol; 1984 May 01; 26(4):419-24. PubMed ID: 6329767
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Blood pressure maintenance in awake dehydrated rats: renin, vasopressin, and sympathetic activity.
    Burnier M, Biollaz J, Brunner DB, Brunner HR.
    Am J Physiol; 1983 Aug 01; 245(2):H203-9. PubMed ID: 6309021
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Humoral and renal effects of MK-421 (enalapril) in hypertensive subjects.
    de Leeuw PW, Hoogma RP, van Soest GA, Tchang PT, Birkenhäger WH.
    J Cardiovasc Pharmacol; 1983 Aug 01; 5(5):731-6. PubMed ID: 6195458
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effects of captopril and enalapril on sodium excretion and blood pressure in sodium-deficient dogs.
    McCaa RE, Gillespie JB.
    Fed Proc; 1984 Apr 01; 43(5):1336-41. PubMed ID: 6323226
    [Abstract] [Full Text] [Related]

  • 36. Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK 421 in essential hypertension.
    Jackson B, McGrath BP, Johnston CI.
    Clin Exp Pharmacol Physiol Suppl; 1982 Apr 01; 7():99-104. PubMed ID: 6291832
    [Abstract] [Full Text] [Related]

  • 37. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors.
    Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Ann Tallant E, Smith RD, Chappell MC.
    Kidney Int; 2005 Nov 01; 68(5):2189-96. PubMed ID: 16221218
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.
    Ajayi AA, Hockings N, Reid JL.
    Br J Clin Pharmacol; 1986 Apr 01; 21(4):349-57. PubMed ID: 3011047
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.